Seres Therapeutics, Inc. (NASDAQ:MCRB) Sees Large Growth in Short Interest

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) saw a significant increase in short interest in the month of May. As of May 15th, there was short interest totalling 799,000 shares, an increase of 30.9% from the April 30th total of 610,400 shares. Based on an average daily trading volume, of 85,200 shares, the days-to-cover ratio is currently 9.4 days. Currently, 12.4% of the company's shares are sold short.

Institutional Trading of Seres Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Avantax Advisory Services Inc. raised its holdings in shares of Seres Therapeutics by 170.9% during the fourth quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock worth $38,000 after purchasing an additional 28,500 shares during the period. Jane Street Group LLC grew its position in shares of Seres Therapeutics by 181.4% during the fourth quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 37,866 shares during the last quarter. SBI Securities Co. Ltd. grew its position in shares of Seres Therapeutics by 221.8% during the first quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock worth $49,000 after acquiring an additional 48,013 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after acquiring an additional 21,679 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Seres Therapeutics by 193.2% during the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock worth $96,000 after acquiring an additional 89,995 shares during the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

Seres Therapeutics Price Performance

MCRB traded down $0.01 during trading on Thursday, hitting $7.12. The company had a trading volume of 13,366 shares, compared to its average volume of 145,379. The company has a market cap of $62.17 million, a PE ratio of -30.96 and a beta of 2.89. The business has a 50-day moving average of $9.11 and a 200-day moving average of $13.79. Seres Therapeutics has a 1-year low of $6.53 and a 1-year high of $30.60.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($1.57). Research analysts forecast that Seres Therapeutics will post -0.38 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Chardan Capital reiterated a "neutral" rating and set a $6.00 price objective (up from $1.25) on shares of Seres Therapeutics in a research note on Thursday, May 8th. The Goldman Sachs Group decreased their price objective on shares of Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a research note on Friday, March 14th. Finally, Wall Street Zen upgraded shares of Seres Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $73.67.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.